Literature DB >> 31850183

Reactive uveitis, retinal vasculitis and scleritis as ocular end-stage of Acanthamoeba keratitis: a histological study.

Lei Shi1,2, Tobias Hager1, Fabian Norbert Fries1, Loay Daas1, Leonard Holbach3, Carmen Hofmann-Rummelt3, Elena Zemova1, Berthold Seitz1, Nóra Szentmáry1,4.   

Abstract

We analysed histologically two Acanthamoeba keratitis (AK) eyes with anterior and posterior segment inflammation and blindness. Two enucleated eyes of 2 patients (age 45 and 51y) with AK (PCR of epithelial abrasion positive) were analysed. Histological analysis was performed using hematoxylin-eosin, periodic acid-Schiff and Gömöri-methenamine silver staining. We could not observe Acanthamoeba trophozoites or cysts neither in the cornea nor in other ocular tissues. Meanwhile, we found uveitis, retinal vasculitis and scleritis in these eyes, due to the long-standing, recalcitrant AK. So in this stage of AK, systemic immune suppression may be necessary for a longer time period. International Journal of Ophthalmology Press.

Entities:  

Keywords:  Acanthamoeba keratitis; enucleation; retinal vasculitis; scleritis; uveitis

Year:  2019        PMID: 31850183      PMCID: PMC6901890          DOI: 10.18240/ijo.2019.12.20

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  27 in total

1.  Tear IgA and serum IgG antibodies against Acanthamoeba in patients with Acanthamoeba keratitis.

Authors:  H Alizadeh; S Apte; M S El-Agha; L Li; M Hurt; K Howard; H D Cavanagh; J P McCulley; J Y Niederkorn
Journal:  Cornea       Date:  2001-08       Impact factor: 2.651

2.  The Effect of Antiamoebic Agents on Viability, Proliferation and Migration of Human Epithelial Cells, Keratocytes and Endothelial Cells, In Vitro.

Authors:  Lei Shi; Tanja Stachon; Berthold Seitz; Stefan Wagenpfeil; Achim Langenbucher; Nóra Szentmáry
Journal:  Curr Eye Res       Date:  2018-03-12       Impact factor: 2.424

3.  Adaptive immune responses to Acanthamoeba cysts.

Authors:  Kathy McClellan; Kevin Howard; Elizabeth Mayhew; Jerry Niederkorn; Hassan Alizadeh
Journal:  Exp Eye Res       Date:  2002-09       Impact factor: 3.467

4.  Chorioretinitis in the contralateral eye of a patient with Acanthamoeba keratitis.

Authors:  K J Johns; D M O'Day; S S Feman
Journal:  Ophthalmology       Date:  1988-05       Impact factor: 12.079

5.  Failure of Acanthamoeba castellanii to produce intraocular infections.

Authors:  Daniel W Clarke; Hassan Alizadeh; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-07       Impact factor: 4.799

6.  Acanthamoeba sclerokeratitis: epidemiology, clinical features, and treatment outcomes.

Authors:  Alfonso Iovieno; Daniel M Gore; Nicole Carnt; John K Dart
Journal:  Ophthalmology       Date:  2014-08-02       Impact factor: 12.079

7.  Are cataract and iris atrophy toxic complications of medical treatment of acanthamoeba keratitis?

Authors:  Niels Ehlers; Jesper Hjortdal
Journal:  Acta Ophthalmol Scand       Date:  2004-04

8.  Effect of immunization with the mannose-induced Acanthamoeba protein and Acanthamoeba plasminogen activator in mitigating Acanthamoeba keratitis.

Authors:  Hassan Alizadeh; Sudha Neelam; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-12       Impact factor: 4.799

Review 9.  Pathobiology and Immunobiology of Acanthamoeba Keratitis: Insights from Animal Models
.

Authors:  Sudha Neelam; Jerry Y Niederkorn
Journal:  Yale J Biol Med       Date:  2017-06-23

10.  Adhesion forces and mechanics in mannose-mediated acanthamoeba interactions.

Authors:  Steven Huth; Julia F Reverey; Matthias Leippe; Christine Selhuber-Unkel
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

View more
  1 in total

1.  Two-step keratoplasty for deep vascularized corneal opacity with severe peripheral thinning following Acanthamoeba keratitis.

Authors:  Karl Anders Knutsson; Giorgio Paganoni; Paolo Rama
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-04-27       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.